Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 31 Aug 16

Research and Markets has announced the addition of the "Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Microscopic Polyangiitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Microscopic Polyangiitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Microscopic Polyangiitis - Overview
  5. Pipeline Products for Microscopic Polyangiitis - Comparative Analysis
  6. Microscopic Polyangiitis - Therapeutics under Development by Companies
  7. Microscopic Polyangiitis - Therapeutics under Investigation by Universities/Institutes
  8. Microscopic Polyangiitis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Microscopic Polyangiitis - Products under Development by Companies
  13. Microscopic Polyangiitis - Products under Investigation by Universities/Institutes
  14. Microscopic Polyangiitis - Companies Involved in Therapeutics Development
  • Coherus BioSciences, Inc.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • Teijin Pharma Limited

For more information about this report visit

Related Topics: Cardiovascular Drugs

View source version on

Business Wire

Last updated on: 31/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.